1. Diosgenin derivatives with structure shown in general formula (I), (II) or (III),

r in the general formulas (I), (II) and (III) are independently H, CH₃，Cl，F，Br，OH，NH₂，NO₂Or OCH₃；

X in the general formulas (I), (II) and (III) is independently C or N.

2. The diosgenin derivative according to claim 1, which is any one of the compounds of the following structural formula:

3. a process for preparing a diosgenin derivative according to claim 1, which comprises at least one of the following (1) to (3):

(1) the preparation method of the diosgenin derivative with the structure shown in the general formula (I) comprises the following steps: carrying out substitution reaction on diosgenin shown in a structural formula 1 and 1, 4-quinones to obtain a target compound shown in a structural general formula I; the preparation method comprises the following synthetic route:

(2) the preparation method of the diosgenin derivative with the structure shown in the general formula (II) comprises the following steps: carrying out substitution reaction on the diosgenin analogue shown in the structural formula 2 and 1, 4-quinones to obtain an intermediate product shown in a structural general formula 3; removing the protecting group of the intermediate product 3 to obtain a target compound shown as a general formula II; the preparation method comprises the following synthetic route:

(3) the preparation method of the diosgenin derivative with the structure shown in the general formula (III) comprises the following steps: carrying out substitution reaction on diosgenin analogues shown in structural formula 4 and 1, 4-quinones to obtain intermediate products shown in structural general formula 5; removing the protecting group of the intermediate product 5 to obtain a target compound shown in a general formula III; the preparation method comprises the following synthetic route:

in the formula: r is H, CH₃，Cl，F，Br，OH，NH₂，NO₂Or OCH₃；

X is C or N.

4. The method of claim 3, wherein the substitution reaction conditions include: potassium carbonate is used as alkali, the reaction temperature is room temperature, and the reaction time is 12 to 24 hours.

5. The method of claim 4, wherein the substitution reaction is carried out by: dissolving diosgenin or its analogs 2, 4 and 1, 4-quinones in anhydrous THF, adding K₂CO₃Reacting at room temperature for 12-24 h; after the reaction is finished, the solvent is recovered, the sample is stirred, and silica gel column chromatography is carried out to obtain a target compound or an intermediate product.

6. The process according to claim 3, wherein the conditions for the deprotection reaction comprise: with Et₃N.3 HF is used as a removing reagent, the reaction temperature is room temperature, and the reaction time is 3-12 h.

7. The method according to claim 6, wherein the deprotection reaction is carried out by: intermediate 3 or 5 was dissolved in anhydrous THF and Et was added₃N.3 HF, reacting for 3-12h at room temperature; after the reaction is finished, quenching the reaction by saturated sodium bicarbonate solution; extracting with ethyl acetate, combining organic phases, washing with water, saturated sodium bicarbonate and saturated salt in sequence, drying with anhydrous sodium sulfate, filtering, concentrating the organic phase, and separating and purifying by column chromatography to obtain the target product.

8. A medical use of a diosgenin derivative according to claim 1 or 2 in the preparation of an anti-tumour medicament.

9. The use of claim 8, wherein the tumor is lung cancer, liver cancer or cervical cancer.

Background

Tumors have long been a serious disease that seriously harms human health. According to the published global cancer data report in the journal CA in 2018, about 1810 ten thousand new cancer confirmed cases and 960 ten thousand death cases are newly added in the global cancer in 2018 (a.ca.cancer.j.clin.,2018,68, 1). According to data statistics, this report indicates that, globally, by age 75, the cumulative risk of developing cancer is 21.4% and the risk of dying from cancer is 17.7%. Cancer can develop in 1 of 5 men or 1 of 6 women; 1 in 8 men or 1 in 10 women will die from cancer. At present, most clinical antitumor drugs have the problems of poor selectivity, large toxic and side effects and easy generation of drug resistance. Therefore, the research on anti-tumor drugs has been one of the hot spots in drug development. The natural product is one of the main sources of the discovery of the drug lead compound, and in the drugs used in modern clinic, the natural source and the drugs produced by taking the natural product as the lead compound through structural modification are more than one third [ J.Nat.Prod.2016,79,631 ]. Therefore, the research on structural modification of natural products with antitumor activity for the development of antitumor drugs has very important economic and social benefits.

Diosgenin is a steroidal sapogenin with a C27 spirostane-type structure that is widely distributed in dioscorea plants. Is an important intermediate for synthesizing various steroid hormones. In recent years, the anti-tumor activity of diosgenin has been reported all the time, but the medical application of diosgenin is limited to a certain extent due to the weak anti-tumor activity of diosgenin.

Disclosure of Invention

The invention aims to carry out structural modification on diosgenin to obtain a compound with remarkably improved anti-tumor activity aiming at the technical problem of weak anti-tumor activity of the diosgenin in the background technology.

The invention also aims to provide a preparation method of the diosgenin derivative.

Another object of the present invention is to provide a medicinal use of the derivative.

The purpose of the invention can be realized by the following technical scheme:

the invention provides a diosgenin derivative with a structure shown in a general formula (I), (II) or (III),

r in the general formulas (I), (II) and (III) are independently H, CH₃，Cl，F，Br，OH，NH₂，NO₂Or OCH₃；

X in the general formulas (I), (II) and (III) is independently C or N.

Part of compounds of the diosgenin derivative are specifically any one of the following structural formula compounds:

the preparation method of the diosgenin derivative comprises at least one of the following steps (1) to (3):

(1) the preparation method of the diosgenin derivative with the structure shown in the general formula (I) comprises the following steps: carrying out substitution reaction on diosgenin shown in a structural formula 1 and 1, 4-quinones to obtain a target compound shown in a structural general formula I; the preparation method comprises the following synthetic route:

(2) the preparation method of the diosgenin derivative with the structure shown in the general formula (II) comprises the following steps: carrying out substitution reaction on the diosgenin analogue shown in the structural formula 2 and 1, 4-quinones to obtain an intermediate product shown in a structural general formula 3; removing the protecting group of the intermediate product 3 to obtain a target compound shown as a general formula II; the preparation method comprises the following synthetic route:

(3) the preparation method of the diosgenin derivative with the structure shown in the general formula (III) comprises the following steps: carrying out substitution reaction on diosgenin analogues shown in structural formula 4 and 1, 4-quinones to obtain intermediate products shown in structural general formula 5; removing the protecting group of the intermediate product 5 to obtain a target compound shown in a general formula III; the preparation method comprises the following synthetic route:

in the formula: r is H, CH₃，Cl，F，Br，OH，NH₂，NO₂Or OCH₃；

X is C or N.

As a preferable embodiment, the conditions of the substitution reaction in the above preparation method include: potassium carbonate is used as alkali, the reaction temperature is room temperature, and the reaction time is 12 to 24 hours.

Further preferably, the process of the substitution reaction is: dissolving diosgenin or its analogs 2, 4 and 1, 4-quinones in anhydrous THF, adding K₂CO₃Reacting at room temperature for 12-24 h; after the reaction is finished, the solvent is recovered, the sample is stirred, and silica gel column chromatography is carried out to obtain a target compound or an intermediate product.

As a preferred technical scheme, the conditions of the reaction for removing the protecting group comprise: with Et₃N.3 HF is used as a removing reagent, the reaction temperature is room temperature, and the reaction time is 3-12 h.

Further preferably, the process of the protecting group removing reaction is as follows: intermediate 3 or 5 was dissolved in anhydrous THF and Et was added₃N.3 HF, reacting for 3-12h at room temperature; after the reaction is finished, quenching the reaction by saturated sodium bicarbonate solution; extracting with ethyl acetate, combining organic phases, washing with water, saturated sodium bicarbonate and saturated salt in sequence, drying with anhydrous sodium sulfate, filtering, concentrating the organic phase, and separating and purifying by column chromatography to obtain the target product.

The diosgenin derivative has medical application in preparing antitumor drugs. Preferably, the tumor is lung cancer, liver cancer or cervical cancer.

The room temperature of the invention is 25 +/-5 ℃.

The invention has the beneficial effects that: the diosgenin derivative disclosed by the invention has the antitumor activity remarkably superior to that of diosgenin, and has a prospect of being developed into a medicament for treating lung cancer, liver cancer or cervical cancer.

Description of the drawings:

FIG. 1 shows diosgenin derivative Dg1¹H-NMR(500MHz，CDCl₃) Spectra.

FIG. 2 shows diosgenin derivative Dg1¹³C-NMR(125MHz，CDCl₃) Spectra.

FIG. 3 shows diosgenin derivative Dg2¹H-NMR(500MHz，CDCl₃) Spectra.

FIG. 4 shows diosgenin derivative Dg2¹³C-NMR(125MHz，CDCl₃) Spectra.

FIG. 5 shows diosgenin derivative Dg3¹H-NMR(500MHz，CDCl₃) Spectra.

FIG. 6 shows diosgenin derivative Dg3¹³C-NMR(125MHz，CDCl₃) Spectra.

FIG. 7 shows diosgenin derivative Dg4¹H-NMR(500MHz，CDCl₃) Spectra.

FIG. 8 shows diosgenin derivative Dg4¹³C-NMR(125MHz，CDCl₃) Spectra.

FIG. 9 shows diosgenin derivative Dg5¹H-NMR(500MHz，CDCl₃) Spectra.

FIG. 10 shows diosgenin derivative Dg5¹³C-NMR(125MHz，CDCl₃) Spectra.

FIG. 11 shows diosgenin derivative Dg6¹H-NMR(500MHz，CDCl₃) Spectra.

FIG. 12 shows diosgenin derivative Dg6¹³C-NMR(125MHz，CDCl₃) Spectra.

FIG. 13 shows diosgenin derivative Dg7¹H-NMR(500MHz，CDCl₃) Spectra.

FIG. 14 shows diosgenin derivative Dg7¹³C-NMR(125MHz，CDCl₃) Spectra.

FIG. 15 shows diosgeninProcess for the preparation of derivative Dg8¹H-NMR(500MHz，CDCl₃) Spectra.

FIG. 16 shows diosgenin derivative Dg9¹³C-NMR(125MHz，CDCl₃) Spectra.

FIG. 17 shows diosgenin derivative Dg8¹H-NMR(500MHz，CDCl₃) Spectra.

FIG. 18 shows diosgenin derivative Dg9¹³C-NMR(125MHz，CDCl₃) Spectra.

Detailed Description

In order to make those skilled in the art better understand the technical solutions of the present invention, the present invention will be further described with reference to the following preferred embodiments, which are only a part of, but not all of the embodiments of the present invention, and the present invention is not limited by the following preferred embodiments. Unless otherwise specified, the reagents used in the examples of the present invention are all commercially available products, and the test methods used are all conventional methods unless otherwise specified.

The overall synthetic route of the target compound of the invention is as follows:

example 1: synthesis of target Compound Dg1

Compound 1(0.12g, 0.3mmol) and 1, 4-quinones (0.30mmol) are dissolved in anhydrous THF and K is added₂CO₃(0.083g,0.6mmol) and reacted at room temperature for 12 h. After completion of the reaction, the solvent was recovered, and the sample was stirred and subjected to silica gel column chromatography to obtain Dg1(0.11g, 60% yield) as a yellow solid.¹H NMR(500MHz,CDCl₃,ppm)δ8.18–8.12(m,1H),8.10–8.05(m,1H),7.78–7.70(m,1H),5.39(d,J＝5.0Hz,1H),4.80–4.70(m,1H),4.40(q,J＝7.6Hz,1H),3.53–3.42(m,1H),3.37(t,J＝10.9Hz,1H),1.09(d,J＝4.3Hz,3H),0.97(t,J＝5.4Hz,3H),0.78(d,J＝6.2Hz,6H).¹³C NMR(125MHz,CDCl₃,ppm)δ180.0,178.8,156.6,139.8,134.4,134.1,131.4,131.0,127.2,127.2,127.1,122.9,109.4,84.4,80.9,67.0,62.3,56.6,50.1,41.8,40.4,39.9,39.8,37.1,36.9,32.2,32.0,31.6,31.6,30.5,29.5,29.0,21.0,19.6,17.3,16.4,14.7.HRMS(ESI-MS)m/z for C₃₇H₄₅ClO₅Na([M+Na]⁺)627.2848,calc.627.2846.

Example 2: synthesis of target Compound Dg2

A yellow solid, Dg2 (51% yield), was obtained according to the synthesis procedure of example 1.¹H NMR(500MHz,CDCl₃,ppm)δ9.01(d,J＝4.7Hz,1H),8.46(d,J＝7.6Hz,1H),7.68(dd,J＝7.8,4.7Hz,1H),5.39(d,J＝5.1Hz,1H),4.91–4.80(m,1H),4.40(q,J＝7.5Hz,1H),3.49–3.42(m,1H),3.36(t,J＝10.9Hz,1H),1.07(s,3H),0.96(d,J＝6.9Hz,4H),0.78(d,J＝5.7Hz,6H).¹³C NMR(125MHz,CDCl₃,ppm)δ178.2,177.9,157.3,154.8,146.8,139.4,135.0,130.1,128.3,128.0,123.1,109.4,84.9,80.9,67.0,62.2,56.5,50.0,41.7,40.4,39.8,39.8,37.1,36.8,32.2,32.0,31.5,31.5,30.4,29.5,28.9,21.0,19.5,17.3,16.4,14.7.HRMS(ESI-MS)m/z for C₃₆H₄₅ClNO₅([M+H]⁺)606.2988,calc.606.2981.

Example 3: synthesis of target Compound Dg3

A yellow solid, Dg3 (48% yield), was obtained according to the synthesis procedure of example 1.¹H NMR(500MHz,CDCl₃,ppm)δ8.33(d,J＝8.0Hz,1H),7.52(d,J＝8.1Hz,1H),5.38(d,J＝4.9Hz,1H),4.86–4.73(m,1H),4.40(q,J＝7.6Hz,1H),3.47(dd,J＝10.8,4.0Hz,1H),3.37(t,J＝11.0Hz,1H),2.76(s,3H),1.07(s,3H),0.97(d,J＝7.2Hz,3H),0.78(d,J＝5.2Hz,6H).¹³C NMR(125MHz,CDCl₃,ppm)δ178.5,178.0,165.3,157.1,146.4,139.5,135.1,129.9,128.0,126.3,123.0,109.4,84.9,81.0,67.0,62.2,56.6,50.1,41.8,40.4,39.9,39.8,37.1,36.8,32.2,32.0,31.5,31.5,30.4,29.5,29.0,25.3,21.0,19.5,17.3,16.4,14.7.HRMS(ESI-MS)m/z for C₃₇H₄₇ClNO₅([M+H]⁺)620.3135,calc.620.3294.

Example 4: synthesis of target Compound Dg4

Compound 2(0.16g, 0.3mmol) and 1, 4-quinones (0.30mmol) were dissolved in anhydrous THF, K was added₂CO₃(0.083g,0.6mmol) and reacted at room temperature for 24 h. After the reaction is finished, the solvent is recovered, the sample is stirred, and the intermediate product 3 is obtained by silica gel column chromatography. Intermediate 3 was then dissolved in THF and Et was added₃And reacting the solution of N.3HF at room temperature for 3 hours, and after the reaction is finished, quenching the reaction by using a saturated sodium bicarbonate solution. Extraction with ethyl acetate, combination of the organic phases, washing with water, saturated sodium bicarbonate and saturated brine in this order, drying over anhydrous sodium sulfate, filtration, concentration of the organic phase, and purification by column chromatography gave Dg4 (58% yield) as a yellow solid.¹H NMR(500MHz,CDCl₃,ppm)δ8.17–8.10(m,1H),8.09–8.03(m,1H),7.78–7.69(m,2H),5.33(d,J＝5.0Hz,1H),4.45(dd,J＝9.9,5.5Hz,1H),4.36(dd,J＝9.8,6.4Hz,1H),4.28(td,J＝7.8,5.0Hz,1H),3.54–3.46(m,1H),3.36–3.29(m,1H),1.06(d,J＝6.7Hz,3H),1.01(s,3H),0.99(d,J＝6.7Hz,3H),0.77(s,3H).¹³C NMR(125MHz,CDCl₃,ppm)δ179.9,178.8,157.1,140.9,134.4,134.0,131.3,131.0,128.8,127.1,127.0,121.6,90.2,83.3,79.6,71.8,65.3,57.1,50.2,42.4,40.8,39.6,38.0,37.4,36.8,34.7,32.4,32.1,31.8,30.9,30.1,20.8,19.6,19.2,16.8,16.6.HRMS(ESI-MS)m/z for C₃₇H₄₇ClO₅Na([M+Na]⁺)629.3000,calc.629.3004.

Example 5: synthesis of target Compound Dg5

A yellow solid, Dg5 (49% yield), was obtained according to the synthesis procedure of example 4.¹H NMR(500MHz,CDCl₃,ppm)δ9.00(dd,J＝4.7,1.7Hz,1H),8.45(dd,J＝7.9,1.7Hz,1H),7.68(dd,J＝7.9,4.7Hz,1H),5.39–5.30(m,1H),4.54(dd,J＝10.0,5.4Hz,1H),4.45(dd,J＝9.9,6.4Hz,1H),4.28(td,J＝7.8,5.1Hz,1H),3.35–3.29(m,2H),3.32(td,J＝7.7,4.1Hz,1H),1.06(d,J＝6.8Hz,3H),1.01(s,3H),0.99(d,J＝6.7Hz,3H),0.78(s,3H).¹³C NMR(125MHz,CDCl₃,ppm)δ178.1,177.9,157.8,154.7,146.8,140.9,140.9,135.0,128.3,128.0,121.6,90.2,83.4,80.0,71.9,65.3,57.1,50.3,42.4,40.8,39.6,38.0,37.4,36.8,34.7,32.4,32.4,32.1,30.9,30.1,29.8,20.8,19.6,19.1,16.8,16.6.HRMS(ESI-MS)m/z for C₃₆H₄₇ClNO₅([M+H]⁺)608.3131,calc.608.3137.

Example 6: synthesis of target Compound Dg6

A yellow solid, Dg6 (52% yield), was obtained according to the synthesis procedure of example 4.¹H NMR(500MHz,CDCl₃,ppm)δ8.32(d,J＝8.0Hz,1H),7.51(d,J＝8.0Hz,1H),4.51(dd,J＝10.0,5.5Hz,1H),4.45–4.36(m,1H),4.28(td,J＝7.8,5.1Hz,1H),3.51(tt,J＝11.3,4.5Hz,1H),3.31(td,J＝7.8,4.1Hz,1H),2.75(s,4H),1.07–1.05(m,3H),1.01(s,3H),0.99(d,J＝6.8,3H),0.78(s,3H).¹³C NMR(125MHz,CDCl₃,ppm)δ178.3,177.9,165.1,157.4,146.2,140.8,134.9,127.9,127.9,126.0,121.4,90.1,83.2,79.8,71.7,65.2,57.0,50.1,42.3,40.7,39.5,37.9,37.3,36.7,34.6,32.3,32.0,31.7,31.6,30.8,30.0,25.2,20.7,19.4,19.0,16.7,16.4.HRMS(ESI-MS)m/z for C₃₇H₄₉ClNO₅([M+H]⁺)622.3292,calc.622.3294.

Example 7: synthesis of target Compound Dg7

Compound 4(0.16g, 0.3mmol) and 1, 4-quinones (0.30mmol) were dissolved in anhydrous THF, K was added₂CO₃(0.083g,0.6mmol) and reacted at room temperature for 24 h. After the reaction is finished, the solvent is recovered, the sample is stirred, and the intermediate product 3 is obtained by silica gel column chromatography. Intermediate 5 was then dissolved in THF and Et was added₃N.3HF solution, room temperature reaction for 3h, silica gel sample, through column chromatography to obtain yellow solid Dg7 (57% yield).¹H NMR(500MHz,CDCl₃,ppm)δ8.15–8.11(m,1H),8.10–8.06(m,1H),7.77–7.70(m,2H),5.39(d,J＝5.0Hz,1H),4.79–4.69(m,1H),4.30(td,J＝7.8,5.2Hz,1H),3.54–3.40(m,3H),3.33(td,J＝8.3,3.7Hz,1H),1.08(s,3H),1.00(d,J＝6.7Hz,3H),0.98(d,J＝6.7Hz,3H),0.81(s,3H).¹³C NMR(125MHz,CDCl₃,ppm)δ180.0,178.9,156.6,139.8,134.4,134.1,131.4,131.0,127.2,127.1,127.1,122.9,90.5,84.4,83.4,68.2,65.3,57.1,50.2,40.9,39.8,39.6,38.1,37.2,36.9,35.9,32.4,32.2,31.7,30.6,30.3,29.5,20.9,19.6,19.1,16.8,16.6.HRMS(ESI-MS)m/z for C₃₇H₄₇ClO₅Na([M+Na]⁺)629.3003,calc.629.3004.

Example 8: synthesis of target Compound Dg8

The synthesis procedure of example 7 was followed to give Dg8 (49% yield) as a yellow solid.¹H NMR(500MHz,CDCl₃,ppm)δ9.01(d,J＝4.6Hz,1H),8.46(d,J＝7.9Hz,1H),7.68(dd,J＝7.8,4.6Hz,1H),5.43–5.35(m,1H),4.85(tt,J＝10.9,4.9Hz,1H),4.30(td,J＝7.8,5.1Hz,1H),4.11(q,J＝7.1Hz,1H),3.54–3.38(m,2H),3.32(td,J＝8.3,3.9Hz,1H),1.07(s,3H),0.99(d,J＝6.6Hz,3H),0.90(d,J＝6.7Hz,3H),0.80(s,3H).¹³C NMR(125MHz,CDCl₃,ppm)δ178.2,177.9,157.3,154.8,146.8,139.5,135.0,130.1,128.4,128.0,123.1,90.5,84.9,83.3,68.2,65.2,57.0,50.1,40.9,39.8,39.5,38.1,37.1,36.8,35.9,32.4,32.1,31.6,30.6,30.3,29.5,20.9,19.5,19.0,16.8,16.6.C₃₆H₄₇ClNO₅([M+H]⁺)608.3141,calc.608.3137.

Example 9: synthesis of target Compound Dg9

A yellow solid SD-3 (53% yield) was obtained by the synthetic method of example 7.¹H NMR(500MHz,CDCl₃,ppm)δ8.37–8.29(m,1H),7.51(d,J＝8.1Hz,1H),5.37(d,J＝5.0Hz,1H),4.77(tt,J＝10.9,5.0Hz,1H),4.29(td,J＝7.8,5.0Hz,1H),4.10(q,J＝7.1Hz,1H),3.48(dd,J＝10.7,6.2Hz,1H),3.42(dd,J＝10.6,6.2Hz,1H),3.31(td,J＝8.3,3.9Hz,1H),2.75(s,3H),1.05(s,3H),0.98(d,J＝6.7Hz,3H),0.89(d,J＝6.8Hz,3H),0.79(s,3H).(125MHz,CDCl₃,ppm)δ178.4,178.0,165.2,157.0,146.3,139.4,135.1,129.8,128.0,126.2,123.0,90.5,84.8,83.3,68.1,65.2,56.9,50.1,40.8,39.8,39.5,38.0,37.1,36.7,35.8,32.3,32.1,31.6,30.6,30.2,29.4,25.3,20.8,19.5,19.0,16.7,16.5.HRMS(ESI-MS)m/z for C₃₇H₄₉ClNO₅([M+H]⁺)622.3299,calc.622.3294.

Example 10: diosgenin derivative antitumor activity test

1. Cell line and reagent material

Lung cancer cells (A549), liver cancer cells (HepG2) and cervical cancer cells (HeLa) were purchased from Shanghai cell Bank of Chinese academy of sciences. DMEM medium, 10% fetal bovine serum, trypsin, MTT, etc.

2. MTT method for detecting survival rate of tumor cells

The derivatives Dg1-Dg9 and diosgenin are respectively dissolved in a small amount of DMSO to prepare the mixture with the concentration of 1.0 × 10²mol/L mother liquor. For administration, the cells were diluted to the corresponding concentration (1.0. mu.M to 100. mu.M) with fresh cell culture DMEM. Tumor cell lines were suspended in DEME medium. At 1 × 10⁴cells/mL were plated in 96-well plates at 37 ℃ in 5% CO₂Incubate for 24h under conditions. Suck awayMedium, then administration. 37 ℃ and 5% CO₂Culturing for 48 h. Then 10. mu.L of MTT solution was added to each well, and the incubation was continued for 4 hours, and the medium was washed away. Add 100. mu.L DMSO per well and shake for 10 min. The absorbance was measured at 490nm and the inhibition was calculated according to the following formula: the cytostatic rate (1-mean absorbance of the administered cell group/absorbance of the control cell group) × 100%, and IC was finally calculated₅₀The value is obtained.

3. Results of the experiment

TABLE 1 diosgenin derivatives

As shown in table 1, the diosgenin derivatives Dg4 and Dg9 in the invention have significant inhibitory effects on a549 and HepG2 respectively, and Dg7 has significant inhibitory effects on three tumor cells, and both of them are significantly superior to diosgenin.